Veru has set a Q1 2026 start for its Phase 2b Plateau study evaluating enobosarm, a selective androgen receptor modulator, as an adjunct to GLP-1 receptor agonists in obesity. The 200-patient trial will enroll individuals with BMI ≥35 who are initiating GLP-1 therapy, with a primary endpoint of percent change in total body weight at 72 weeks and a 36-week interim analysis of fat and lean mass by DEXA. Key secondary measures span total fat and lean mass, bone mineral density, a stair-climb test, and patient-reported physical function. The plan follows positive findings from Veru’s earlier Phase 2b Quality study in older adults receiving semaglutide, which suggested enobosarm preserved lean mass and physical function while driving greater fat loss over 16 weeks, with an extension phase exploring enobosarm monotherapy after GLP-1 discontinuation.
The strategic question is whether “quality of weight loss” becomes the next competitive battleground in obesity. GLP-1s are highly effective but are associated with reductions in lean mass, a liability for older patients and those at risk of frailty. Veru’s thesis is that safeguarding muscle while selectively reducing fat can increase energy expenditure and extend the trajectory of weight loss beyond the familiar plateau. If the Plateau study confirms clinically meaningful additional weight loss plus objective gains in body composition and function, enobosarm could define an add-on category rather than compete head-to-head with incretin leaders.
The timing matters. Payers are retooling coverage in real time as GLP-1 use expands into cardiometabolic prevention, and employers are demanding demonstrable functional benefits to justify long-term costs. HCPs are seeking guidance on how to monitor and manage lean mass loss in older and high-BMI patients as GLP-1 treatment durations lengthen. A therapy that preserves muscle, maintains bone health, and improves functional status could shift care pathways, from baseline DEXA utilization to routine performance assessments, and could offer Medical Affairs a clear mandate for education and real-world data generation. For patients, especially those over 60, a composition-focused adjunct could reduce falls, frailty, and disability—outcomes that resonate with payers’ total-cost-of-care models.
Competitive dynamics are equally pointed. While Novo Nordisk and Eli Lilly are advancing dual and triple agonists and amylin combinations to push efficacy ceilings, few programs explicitly tackle lean mass preservation as a primary value proposition. Alternatives such as myostatin inhibitors, exercise mimetics, and other anabolic strategies are circling the same clinical need, but SARMs offer a pharmacology that is straightforward to measure with DEXA and functional endpoints. If Veru can produce compelling, durable 72-week data, the asset could be a partnering candidate for incretin portfolios or a platform adjunct across GLP-1 brands.
Regulatory and execution risks will shape the path. Demonstrating additive weight loss versus GLP-1 alone is pivotal for approval, but payers may be equally persuaded by functional outcomes and bone health if tied to hard endpoints and credible health economics. Trial operations must navigate GLP-1 access constraints, sourcing of background therapy, and the need for rigorous safety characterization of a SARM class drug over long durations. Veru’s broader pipeline, including sabizabulin for inflammatory pathways in atherosclerotic disease, indicates a cardiometabolic focus that could amplify cross-asset medical narratives and payer dialogues.
The next 18 months will reveal whether an adjunct that upgrades the quality and durability of GLP-1-driven weight loss can earn a distinct place in formularies and guidelines. Will enobosarm establish body composition and functional preservation as must-have endpoints in obesity care, or will next-generation incretin combinations blunt the need for a separate add-on before the category takes root?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
